FDA OKs Another Injectable for Rare Kidney Disorder

(MedPage Today) -- Nedosiran (Rivfloza), a once-monthly RNA interference (RNAi) injection, gained FDA approval for certain patients with primary hyperoxaluria type 1 (PH1), drugmaker Novo Nordisk announced Monday. The lactate dehydrogenase A-directed...
Source: MedPage Today Pediatrics - Category: Pediatrics Source Type: news